IO Biotech Inc. (IOBT)
IO Biotech Statistics
Share Statistics
IO Biotech has 65.88M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 65.88M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 29.89% |
| Shares Floating | 48.45M |
| Failed to Deliver (FTD) Shares | 13.78K |
| FTD / Avg. Volume | 8.31% |
Short Selling Information
The latest short interest is 128.33K, so 0.19% of the outstanding shares have been sold short.
| Short Interest | 128.33K |
| Short % of Shares Out | 0.19% |
| Short % of Float | 0.53% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -0.63 and the forward PE ratio is -0.83. IO Biotech's PEG ratio is 0.02.
| PE Ratio | -0.63 |
| Forward PE | -0.83 |
| PS Ratio | 0 |
| Forward PS | 0.3 |
| PB Ratio | 1.29 |
| P/FCF Ratio | -0.74 |
| PEG Ratio | 0.02 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for IO Biotech.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.33, with a Debt / Equity ratio of 0.04.
| Current Ratio | 3.33 |
| Quick Ratio | 3.33 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | -0.02 |
| Debt / FCF | -0.02 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.19M |
| Employee Count | 80 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 1.44M |
| Effective Tax Rate | -1.53% |
Stock Price Statistics
The stock price has increased by -36.3% in the last 52 weeks. The beta is 0.08, so IO Biotech's price volatility has been higher than the market average.
| Beta | 0.08 |
| 52-Week Price Change | -36.3% |
| 50-Day Moving Average | 0.96 |
| 200-Day Moving Average | 1.05 |
| Relative Strength Index (RSI) | 50.52 |
| Average Volume (20 Days) | 165.88K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -95.18M |
| Net Income | -95.49M |
| EBITDA | -95.18M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.45 |
Balance Sheet
The company has 60.03M in cash and 1.92M in debt, giving a net cash position of 58.12M.
| Cash & Cash Equivalents | 60.03M |
| Total Debt | 1.92M |
| Net Cash | 58.12M |
| Retained Earnings | -359.31M |
| Total Assets | 67.7M |
| Working Capital | 45.47M |
Cash Flow
In the last 12 months, operating cash flow was -82.35M and capital expenditures -44K, giving a free cash flow of -82.39M.
| Operating Cash Flow | -82.35M |
| Capital Expenditures | -44K |
| Free Cash Flow | -82.39M |
| FCF Per Share | -1.25 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
IOBT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for IOBT is $10, which is 975.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $10 |
| Price Target Difference | 975.3% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Scores
| Altman Z-Score | -9.53 |
| Piotroski F-Score | 1 |